newsfilter
← Latest News
GlobeNewswire·

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

  • Kura Oncology & Kyowa Kirin announced eight accepted abstracts on ziftomenib for the 2026 ASH Annual Meeting in New Orleans (December 12-15).
  • Two oral presentations will report first-in-human combination data for ziftomenib with quizartinib in newly diagnosed NPM1/FLT3 co-mutated AML (KOMET-007) & gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML (KOMET-008).
  • Longer-term Phase 1b data on ziftomenib plus venetoclax & azacitidine in frontline AML will support the ongoing Phase 3 KOMET-017 registrational study.
  • An exploratory analysis will evaluate ziftomenib clinical activity in R/R AML subtypes beyond NPM1-mutated & KMT2A-rearranged disease, focusing on MEIS1-associated genomic alterations.
  • Additional oral presentations will cover initial results from the pediatric PedAL trial (ziftomenib with fludarabine & cytarabine) & preclinical findings on SETBP1-mutant leukemias.
  • A live investor webcast & conference call featuring Kura management & external experts is scheduled for December 15, 2026, at 8:30 a.m. ET.
  • All eight abstracts related to ziftomenib are available on the ASH website, including details on specific session times & locations.
  • KOMZIFTI (ziftomenib) carries a Boxed Warning for differentiation syndrome, which can be fatal, & warnings for QTc interval prolongation & embryo-fetal toxicity.
  • The most common adverse reactions (≥20%) include increased transaminases, infections, decreased potassium, decreased albumin, hemorrhage, & diarrhea.
  • Drug interactions require avoiding strong/moderate CYP3A4 inducers & concomitant use of drugs that prolong the QTc interval, with specific timing modifications for gastric acid reducing agents.